Skip to main content
. 2021 Oct 9;13(10):1649. doi: 10.3390/pharmaceutics13101649

Figure 8.

Figure 8

Self-assembled DNA nanoclew for CRISPR/Cas9 RNP delivery. (A) Design of the DNA nanoclew to deliver the CRISPR-Cas9 RNP complex. (B) In vivo gene editing of Cas9 RNP in U2OS. EGFP xenograft tumors. The EGFP stained by antibodies appears green, and the nuclei appears blue. Approximately 25% of the tumor cells near the injection site showed no EGFP expression and the untreated mice did not show any loss. Reproduced with permission from [58]. Copyright John Wiley and Sons, 2015.